Abstract
The introduction of novel drugs in multiple myeloma therapy has changed disease survivals in last 15 years. Besides to be more effective in this disease new agents have been utilized in novel strategies such as consolidation and maintenance therapy. Lenalidomide has been one of the favourite in clinical trials because of its oral administration, and bortezomib has been utilized too after the drug has been proved to be effective subcutaneously. Advances in the understanding of disease biology and genetics could give a risk stratification to identify those patients who can benefit more and to better drive maintenance therapy in the future.
Keywords: Bortezomib, chemotherapy, IMID's, myeloma, new agents.
Graphical Abstract
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
43
4
1